Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619719 · ClinicalTrials.gov registry record · NA
Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia
A NA study, sponsored by Legacy Health System.
- Terminated
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT04619719 is a NA study that was terminated before completion, run by Legacy Health System. The registered enrollment target is 27 participants.
The verdict
NCT04619719, a NA study, was terminated before completion, sponsored by Legacy Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Of the many treatments proposed for COVID-19, few directly address the severe hypoxia among COVID-19 patients. Interim results from our single-center, non-randomized clinical trial (NCT04332081) suggest that hyperbaric oxygen therapy may reduce inpatient mortality or the need for mechanical ventilation among COVID-19 patients by more than half. Hyperbaric oxygen therapy is delivered by increasing the atmospheric pressure surrounding a patient, which results in increased oxygen delivery to a patient's blood at a rate higher than any other available modality. It is already FDA-approved for several indications, including conditions with impaired gas exchange and severe infectious processes. Furthermore, several studies have found that hyperbaric oxygen therapy inhibits the production of proinflammatory cytokines, which may play a role in the pathophysiology of COVID-19. The goal of this proposal is to perform a multi-center, randomized controlled trial to evaluate the short-term and long-term efficacy of hyperbaric oxygen therapy for COVID-19 patients. This proposal will rigorously test whether hyperbaric oxygen therapy can reduce the substantial mortality and morbidity of this challenging disease.
Interventions
- DEVICE Hyperbaric Oxygen Therapy (HBOT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2023-02-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04619719
The ClinicalTrials.gov registry entry for NCT04619719 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Legacy Health System, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperbaric Oxygen Therapy (HBOT) is the first listed.
NCT04619719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04619719 about?
NCT04619719 is a clinical study titled "Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia". Of the many treatments proposed for COVID-19, few directly address the severe hypoxia among COVID-19 patients. Interim results from our single-center, non-randomized clinical trial (NCT04332081) suggest that hyperbaric oxygen therapy may reduce inpatient mortality or the need for mechanical ventilat...
What is the current status of trial NCT04619719?
This trial is currently terminated. It is a NA study. The enrollment target is 27 participants. The study started on 2021-03-15. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT04619719?
The interventions under investigation include: Hyperbaric Oxygen Therapy (HBOT) (DEVICE).
Who is sponsoring clinical trial NCT04619719?
This trial is sponsored by Legacy Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.